IGM Biosciences Inc (IGMS) Q1 2024 Earnings: Aligns with EPS Projections Amidst Clinical ...
2024 Financial Guidance: Expects full-year 2024 GAAP operating expenses between $210 million to $220 million and collaboration revenue of approximately $63 million. Future Outlook: Anticipates ending 2024 with approximately $180 million in cash and investments, sufficient to fund operations into the second quarter of 2026.
IGM Biosciences' most advanced project, aplitabart, is being tested in a clinical trial for metastatic colorectal cancer.
Detailed price information for Igm Financial Inc (IGM-T) from The Globe and Mail including charting and trades.
Investors might want to bet on IGM Biosciences, Inc. (NASDAQ:IGMS), as it has been recently upgraded to a Zacks Rank #2 ...
The IGM noted with concern the Prime Minister’s tone in the press conference held on Monday during which he accused some journalists and their media houses of working for the so-called ...
The board of IGM Financial Inc. (TSE:IGM) has announced that it will pay a dividend on the 31st of July, with investors ...
At his speech at the annual meeting, O’Sullivan said: “Today, IGM’s realigned business gives us a blueprint for meaningful ...
IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops ...
Detailed price information for Igm Financial Inc (IGM-T) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback